Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim of the study is to identify a predictive molecular signature for response to chemotherapy, according to WHO criteria, in patients with non-small cell lung cancer by studying the transcriptome (miRNAs and mRNAs) and the single nucleotide polymorphism (SNPs) by using high throughput techniques.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: European Lung Cancer Working Party

Criteria

Inclusion Criteria:

• Histological diagnosis of non-small-cell lung cancer (NSCLC)

• Obtention of a biopsy of the tumour according to the procedure defined in the protocol

• NSCLC of any stage to be treated by standard conventional first-line chemotherapy, as defined in the ELCWP guidelines (www.elcwp.org)

• Presence of at least one assessable lesion

• Availability for participating in the detailed follow-up of the protocol

• Signed informed consent.

• Age above 18 years

Exclusion Criteria:

• Patient who was previously treated with chemotherapy for NSCLC or who has any contra-indication precluding the administration of conventional chemotherapy for NSCLC

• NSCLC treated by exclusive surgery or radiotherapy

• A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval)